3.3.1. Proportions of patients achieving CDC
INFLAMMATORY BOWEL DISEASE, REMISSION, DISEASE
To assess the treatment benefits of filgotinib 200 mg in individuals, we evaluated the proportions of patients who achieved the exploratory composite endpoint, CDC [comprising pMCS remission, endoscopic improvement, inflammatory biomarker remission and IBDQ remission] at weeks 10 and 58. In the overall induction population, CDC was achieved by greater proportions of filgotinib 200 mg-treated than placebo-treated patients [10.9% vs 2.9%, Proportions of patients achieving CDC and its component outcomes in Induction Studies A and B at week 10 and in the Maintenance Study at week 58





CDC, Comprehensive Disease Control; CI, confidence interval; HRQoL, health-related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; pMCS, partial Mayo Clinic Score.